14 Dec, 2023 What is the Actual Impact of the Biden Administration’s New March-In Guidance? By Kristen Riemenschneider Joshua Samuel The Bayh-Dole Act of 1980 provides certain rights in favor of the U.S. government in order to ensure that products arising from federally...
30 May, 2023 Key Takeaways from the 21st Annual Biomed Israel Conference By Ben Cohen The 21st annual Biomed Israel Conference, attended by thousands of industry leaders from 45 countries, presented a juxtaposition of...
24 May, 2023 Ongoing Initiatives at the USPTO and FDA and Their Potential Impact on the Life Sciences Industry in the United States By Kristen Riemenschneider Jeff Jay Jake Silvers In the past few months, proposals from the United States Patent and Trademark Office (“USPTO”) have drawn the attention of organizations,...
12 Apr, 2023 The Drug Pricing Landscape in 2023: The Shifting Sands of Progress By Kristen Riemenschneider Joshua Samuel In our January blog post on this topic, The Drug Pricing Landscape in 2023: Renewed Pressure for Pricing Reform, we speculated that in...